The Food and Drug Administration (FDA) recently approved the following oncology drugs: 

• FDA Approves Cemiplimab-rwlc in Combination With Platinum-based Chemotherapy For Non-small Cell Lung Cancer
• FDA Approves Brentuximab Vedotin in Combination With Chemotherapy For Pediatric Patients With Classical Hodgkin Lymphoma
• FDA Approves Tremelimumab In Combination With Durvalumab and Platinum-Based Chemotherapy For Metastatic Non-Small Cell Lung Cancer
• FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-Gynx For Frα Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Please visit the FDA Hematology/Oncology (Cancer) Approvals & Safety Notifications webpage for a list of current and past approvals.